
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
    <title>GI Intelligence Terminal</title><script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        :root { --primary: #3498db; --success: #2ecc71; --warning: #ffb300; --bg: #f5f7fa; --text: #2c3e50; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); margin: 0; padding: 8px; }
        .card { background: #fff; border-radius: 12px; padding: 12px; box-shadow: 0 2px 8px rgba(0,0,0,0.05); margin-bottom: 12px; border: 1px solid #e0e0e0; }
        
        /* ğŸ© ë„í‘œ ì¤‘ì•™ ë°°ì¹˜ ìŠ¤íƒ€ì¼ */
        .chart-container { background: #fff; border-radius: 12px; padding: 12px; border: 1px solid #e0e0e0; height: 160px; display: flex; justify-content: center; margin-bottom: 12px; }
        
        .paper-item { margin-bottom: 8px; border-radius: 10px; overflow: hidden; list-style: none; border: 1px solid #eee; }
        summary { padding: 12px; cursor: pointer; outline: none; list-style: none; }
        summary::-webkit-details-marker { display: none; }
        .meta { font-size: 0.7rem; color: #7f8c8d; margin-bottom: 4px; display: flex; align-items: center; gap: 4px; flex-wrap: wrap; }
        .title-row { font-weight: bold; font-size: 0.9rem; line-height: 1.4; display: flex; align-items: flex-start; }
        .arrow-icon { display: inline-block; transition: transform 0.2s; color: var(--primary); margin-right: 6px; flex-shrink: 0; }
        details[open] .arrow-icon { transform: rotate(90deg); }
        .badge { padding: 1px 4px; border-radius: 3px; font-size: 0.6rem; font-weight: bold; color: #fff; }
        .rct { background: #e74c3c; } .gl { background: var(--success); } .if { background: #8e44ad; }
        .content { padding: 12px; background: #f9f9f9; border-top: 1px solid #eee; font-size: 0.85rem; }
        .clinical-note { background: #fff8e1; border-left: 3px solid var(--warning); padding: 10px; border-radius: 6px; margin-bottom: 10px; font-size: 0.8rem; color: #5d4037; }
        .btm-box { background: #ebf5ff; padding: 10px; border-radius: 6px; margin-bottom: 10px; border-left: 3px solid var(--primary); font-weight: bold; }
        .btn { flex: 1; padding: 8px; border-radius: 6px; text-align: center; text-decoration: none; font-weight: bold; cursor: pointer; font-size: 0.8rem; border: none; color: #fff; }
        .pub { background: var(--primary); } .shr { background: var(--success); }
        h3 { font-size: 1.1rem; margin: 15px 0 10px 0; border-bottom: 2px solid #eee; padding-bottom: 5px; }
    </style>
</head>
<body>
    <div class="card" style="text-align:center;">
        <h1 style="margin:0; font-size:1.4rem;">ğŸ¥ GI Intel Terminal</h1>
        <small style="font-size:0.75rem;">Updated: 2026-02-27 14:06 KST</small>
    </div>
    
    <div class="card" style="border-top: 5px solid #e74c3c;">
        <h2 style="margin-top:0; font-size:1rem; color:#e74c3c;">ğŸ”¥ Weekly Top 3 (Practice-Changing)</h2>
        
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>The Cochrane database of systematic reviews</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Protocol available via doi.org/10.1002/14651858.CD015266.</div>
            <div class="abs">The role of nonsteroidal anti-inflammatory drugs, particularly aspirin, in the primary prevention of colorectal cancer remains controversial. The debate over aspirin use is driven by the challenge of balancing uncertain preventive benefits against the risks of adverse effects. Given the inconsistent findings from clinical trials and conflicting clinical guidelines, a rigorous and updated systematic review is necessary to clarify the evidence base.<br><br>To assess the benefits and harms of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, for preventing colorectal cancer (CRC) and colorectal adenoma (CRA) in the general population.<br><br>We searched CENTRAL, MEDLINE, Embase, and two clinical trial registers (ClinicalTrials.gov and WHO ICTRP) on 3 March 2025.<br><br>We included parallel-group or factorial-design randomized controlled trials (RCTs) comparing aspirin and other NSAIDs with either no treatment or a different treatment for preventing CRC or CRA in the general population.<br><br>Our critical outcomes were CRC incidence and serious adverse events (SAE). Our important outcomes included CRC mortality, CRA incidence, serious extracranial hemorrhage, and hemorrhagic stroke. When data were available, we categorized findings into prespecified follow-up intervals: 5 to < 10 years, 10 to < 15 years, and â‰¥ 15 years.<br><br>We assessed the risk of bias for study outcomes as high risk, some concerns, or low risk, using the Cochrane RoB 2 tool.<br><br>We synthesized data for each outcome using random-effects meta-analysis. For time-dependent outcomes, we prioritized time-to-event data, calculating hazard ratios (HRs) with 95% confidence intervals (CIs). When these were unavailable, we used dichotomous data to calculate risk ratios (RRs). For rare outcomes, we calculated Peto odds ratios (ORs) using a fixed-effect model. We used GRADE to assess the certainty of the evidence.<br><br>We included 10 RCTs involving a total of 124,837 participants. These studies compared aspirin with either placebo or no treatment for the primary prevention of CRC. Low-dose aspirin (75 to 100 mg per day) was typically used, though three studies evaluated higher doses. The studies were mostly conducted in Europe and North America. One study had sites in Australia, and there were two large studies conducted in Japan. Seven studies reported long-term results with extended observational follow-up where blinding had ceased. We did not identify any RCTs that evaluated the use of non-aspirin NSAIDs by the general population for primary CRC prevention.<br><br>For the comparison of aspirin versus inactive control in the general population, we rated the certainty of the evidence as very low to high. We downgraded the certainty level for several outcomes due primarily to risk of bias and imprecision. Regarding CRC incidence, aspirin probably results in little to no difference at follow-up â‰¥ 5 to < 10 years (HR 1.00, 95% CI 0.81 to 1.24; 3 studies, 26,702 participants; moderate-certainty evidence) and at â‰¥ 10 to < 15 years (HR 0.95, 95% CI 0.77 to 1.17; 2 studies, 42,412 participants; moderate-certainty evidence). Aspirin may reduce CRC incidence slightly at follow-up â‰¥ 15 years (HR 0.78, 95% CI 0.67 to 0.91; 3 studies, 47,464 participants; very low-certainty evidence), but the evidence is very uncertain. Regarding CRC mortality, aspirin may increase mortality at follow-up â‰¥ 5 to < 10 years (HR 1.77, 95% CI 1.02 to 3.07; 1 study, 19,114 participants; low-certainty evidence), may result in little to no difference in mortality at follow-up â‰¥ 10 years and < 15 years (Peto OR 1.14, 95% CI 0.73 to 1.78; 1 study, 39,876 participants; low-certainty evidence), but may reduce mortality at follow-up â‰¥ 15 years (Peto OR 0.74, 95% CI 0.60 to 0.90; 5 studies, 53,909 participants; very low certainty evidence), but the evidence is very uncertain. Regarding CRA incidence, aspirin may result in little to no difference in CRA incidence at â‰¥ 5 to < 10 years of follow-up (Peto OR 0.42, 95% CI 0.10 to 1.87; 1 study, 12,546 participants; very low certainty evidence), but the evidence is very uncertain. Regarding safety, although aspirin probably results in little to no difference in overall SAE (RR 1.06, 95% CI 0.84 to 1.34; 3 studies, 16,442 participants; moderate-certainty evidence), aspirin does increase the risk of serious extracranial hemorrhage (RR 1.59, 95% CI 1.30 to 1.95; 8 studies, 97,567 participants; high-certainty evidence) and probably increases the risk of hemorrhagic stroke (Peto OR 1.40, 95% CI 1.11 to 1.77; 8 studies, 105,037 participants; moderate-certainty evidence).<br><br>It is not possible to draw definitive conclusions or outline specific implications for the routine use of aspirin for CRC primary prevention based on the current evidence. Our findings reveal complex, time-dependent preventive effects and concerns about potential harms for clinicians and patients to consider. Evidence of very low to moderate certainty shows little to no benefit for CRC or CRA incidence in the first 15 years, and low-certainty evidence suggests a potential increase in CRC mortality in the first 5 to 10 years. Very low-certainty evidence suggests potential benefits for CRC incidence and mortality after long-term follow-up (â‰¥ 15 years), but these potential long-term benefits are derived from findings in the observational follow-up phases of RCTs, where standard intention-to-treat analyses are not robust to post-randomization confounding from factors such as treatment contamination. The uncertain and delayed potential for benefit must be weighed against a definite harm. While aspirin probably has little to no effect on overall serious adverse events (moderate-certainty evidence), it increases the risk of serious extracranial hemorrhage (high-certainty evidence) and probably increases the risk of serious extracranial hemorrhage (moderate-certainty evidence). In light of the mixed evidence, clinical practice should continue to center on an individualized assessment and a shared decision-making process, carefully balancing a patient's established cardiovascular risk profile against their risk of bleeding.<br><br>This Cochrane review was funded (in part) by the China Postdoctoral Science Foundation (2024M752248) and the Postdoctoral Fellowship Program (Grade A) of China Postdoctoral Science Foundation (BX20230244).<br><br>Protocol available via doi.org/10.1002/14651858.CD015266.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41740630/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41740630')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41740630" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population.\nğŸ¥ The Cochrane database of systematic reviews\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740630/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Giornale italiano di cardiologia (2006)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>[Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="abs">The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738421/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738421')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738421" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ [Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].\nğŸ¥ Giornale italiano di cardiologia (2006)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738421/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:5px solid #e74c3c;background:#fffafa;">
        <summary>
            <div class="meta"> <b>Journal of personalized medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ IL-12/23 ë°˜ì‘ í‰ê°€</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="abs">Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745409/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745409')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745409" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.\nğŸ¥ Journal of personalized medicine\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745409/</textarea>
        </div>
    </details>
    </div>

    <div class="chart-container">
        <canvas id="c2"></canvas>
    </div>

    <div class="card">
        <button id="fBtn" onclick="toggleF()" style="width:100%; padding:10px; border-radius:20px; border:1px solid var(--success); background:#fff; color:var(--success); font-weight:bold; cursor:pointer; font-size: 0.85rem;">ğŸ“‹ ê°€ì´ë“œë¼ì¸ë§Œ ë³´ê¸°</button>
        <div class='sec-group'><h3>ğŸ GI Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The Cochrane database of systematic reviews</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Protocol available via doi.org/10.1002/14651858.CD015266.</div>
            <div class="abs">The role of nonsteroidal anti-inflammatory drugs, particularly aspirin, in the primary prevention of colorectal cancer remains controversial. The debate over aspirin use is driven by the challenge of balancing uncertain preventive benefits against the risks of adverse effects. Given the inconsistent findings from clinical trials and conflicting clinical guidelines, a rigorous and updated systematic review is necessary to clarify the evidence base.<br><br>To assess the benefits and harms of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, for preventing colorectal cancer (CRC) and colorectal adenoma (CRA) in the general population.<br><br>We searched CENTRAL, MEDLINE, Embase, and two clinical trial registers (ClinicalTrials.gov and WHO ICTRP) on 3 March 2025.<br><br>We included parallel-group or factorial-design randomized controlled trials (RCTs) comparing aspirin and other NSAIDs with either no treatment or a different treatment for preventing CRC or CRA in the general population.<br><br>Our critical outcomes were CRC incidence and serious adverse events (SAE). Our important outcomes included CRC mortality, CRA incidence, serious extracranial hemorrhage, and hemorrhagic stroke. When data were available, we categorized findings into prespecified follow-up intervals: 5 to < 10 years, 10 to < 15 years, and â‰¥ 15 years.<br><br>We assessed the risk of bias for study outcomes as high risk, some concerns, or low risk, using the Cochrane RoB 2 tool.<br><br>We synthesized data for each outcome using random-effects meta-analysis. For time-dependent outcomes, we prioritized time-to-event data, calculating hazard ratios (HRs) with 95% confidence intervals (CIs). When these were unavailable, we used dichotomous data to calculate risk ratios (RRs). For rare outcomes, we calculated Peto odds ratios (ORs) using a fixed-effect model. We used GRADE to assess the certainty of the evidence.<br><br>We included 10 RCTs involving a total of 124,837 participants. These studies compared aspirin with either placebo or no treatment for the primary prevention of CRC. Low-dose aspirin (75 to 100 mg per day) was typically used, though three studies evaluated higher doses. The studies were mostly conducted in Europe and North America. One study had sites in Australia, and there were two large studies conducted in Japan. Seven studies reported long-term results with extended observational follow-up where blinding had ceased. We did not identify any RCTs that evaluated the use of non-aspirin NSAIDs by the general population for primary CRC prevention.<br><br>For the comparison of aspirin versus inactive control in the general population, we rated the certainty of the evidence as very low to high. We downgraded the certainty level for several outcomes due primarily to risk of bias and imprecision. Regarding CRC incidence, aspirin probably results in little to no difference at follow-up â‰¥ 5 to < 10 years (HR 1.00, 95% CI 0.81 to 1.24; 3 studies, 26,702 participants; moderate-certainty evidence) and at â‰¥ 10 to < 15 years (HR 0.95, 95% CI 0.77 to 1.17; 2 studies, 42,412 participants; moderate-certainty evidence). Aspirin may reduce CRC incidence slightly at follow-up â‰¥ 15 years (HR 0.78, 95% CI 0.67 to 0.91; 3 studies, 47,464 participants; very low-certainty evidence), but the evidence is very uncertain. Regarding CRC mortality, aspirin may increase mortality at follow-up â‰¥ 5 to < 10 years (HR 1.77, 95% CI 1.02 to 3.07; 1 study, 19,114 participants; low-certainty evidence), may result in little to no difference in mortality at follow-up â‰¥ 10 years and < 15 years (Peto OR 1.14, 95% CI 0.73 to 1.78; 1 study, 39,876 participants; low-certainty evidence), but may reduce mortality at follow-up â‰¥ 15 years (Peto OR 0.74, 95% CI 0.60 to 0.90; 5 studies, 53,909 participants; very low certainty evidence), but the evidence is very uncertain. Regarding CRA incidence, aspirin may result in little to no difference in CRA incidence at â‰¥ 5 to < 10 years of follow-up (Peto OR 0.42, 95% CI 0.10 to 1.87; 1 study, 12,546 participants; very low certainty evidence), but the evidence is very uncertain. Regarding safety, although aspirin probably results in little to no difference in overall SAE (RR 1.06, 95% CI 0.84 to 1.34; 3 studies, 16,442 participants; moderate-certainty evidence), aspirin does increase the risk of serious extracranial hemorrhage (RR 1.59, 95% CI 1.30 to 1.95; 8 studies, 97,567 participants; high-certainty evidence) and probably increases the risk of hemorrhagic stroke (Peto OR 1.40, 95% CI 1.11 to 1.77; 8 studies, 105,037 participants; moderate-certainty evidence).<br><br>It is not possible to draw definitive conclusions or outline specific implications for the routine use of aspirin for CRC primary prevention based on the current evidence. Our findings reveal complex, time-dependent preventive effects and concerns about potential harms for clinicians and patients to consider. Evidence of very low to moderate certainty shows little to no benefit for CRC or CRA incidence in the first 15 years, and low-certainty evidence suggests a potential increase in CRC mortality in the first 5 to 10 years. Very low-certainty evidence suggests potential benefits for CRC incidence and mortality after long-term follow-up (â‰¥ 15 years), but these potential long-term benefits are derived from findings in the observational follow-up phases of RCTs, where standard intention-to-treat analyses are not robust to post-randomization confounding from factors such as treatment contamination. The uncertain and delayed potential for benefit must be weighed against a definite harm. While aspirin probably has little to no effect on overall serious adverse events (moderate-certainty evidence), it increases the risk of serious extracranial hemorrhage (high-certainty evidence) and probably increases the risk of serious extracranial hemorrhage (moderate-certainty evidence). In light of the mixed evidence, clinical practice should continue to center on an individualized assessment and a shared decision-making process, carefully balancing a patient's established cardiovascular risk profile against their risk of bleeding.<br><br>This Cochrane review was funded (in part) by the China Postdoctoral Science Foundation (2024M752248) and the Postdoctoral Fellowship Program (Grade A) of China Postdoctoral Science Foundation (BX20230244).<br><br>Protocol available via doi.org/10.1002/14651858.CD015266.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41740630/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41740630')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41740630" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population.\nğŸ¥ The Cochrane database of systematic reviews\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740630/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in pharmacology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.</div>
            <div class="abs">Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.<br><br>A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.<br><br>GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68-0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68-0.96) and liver cancer (HR: 0.74; 95% CI: 0.62-0.88). Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61-0.95). Findings were consistent across sensitivity analyses.<br><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.<br><br>https://osf.io/3rv6d/overview.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41743116/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41743116')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41743116" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.\nğŸ¥ Frontiers in pharmacology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41743116/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>BMC medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The STELLAR trial was registered at ClinicalTrials.gov (identifier: NCT02533271); however, this post hoc analysis was retrospectively conducted.</div>
            <div class="abs">The survival benefit of adjuvant chemotherapy after chemoradiotherapy in locally advanced rectal cancer (LARC) remains unproven, whereas total neoadjuvant therapy (TNT) incorporating preoperative chemotherapy has demonstrated improved outcomes. However, the total chemotherapy duration delivered across neoadjuvant and adjuvant phases varies substantially in clinical practice. We investigated the impact of total chemotherapy duration in the STELLAR trial.<br><br>This post hoc analysis was based on the phase III randomized trial, comparing short-course radiotherapy followed by four cycles of chemotherapy (TNT) with long-course chemoradiotherapy (CRT) in LARC patients. Five hundred thirty-nine patients with available chemotherapy duration data were included, with a median follow-up of 68.1 months. Patients were categorized: group 1 (no chemotherapy, nâ€‰=â€‰121), group 2 (3 to 12 weeks, nâ€‰=â€‰113), group 3 (15 weeks, nâ€‰=â€‰30), and group 4 (â‰¥â€‰18 weeks, nâ€‰=â€‰275). Disease-free survival (DFS), overall survival (OS), distant metastasis (DM), and locoregional recurrence (LRR) were assessed using time-dependent Cox regression.<br><br>Group 4 achieved the highest 5-year OS (82.1%) and DFS (66.0%) rates. Compared with groups 1 and 2, group 4 demonstrated significantly improved OS (adj. Pâ€‰â‰¤â€‰0.001) and improved DFS versus group 1 (HR 0.621, 95% CI 0.443-0.870, adj. Pâ€‰=â€‰0.017). In the TNT cohort, group 4 was associated with significantly improved OS and DFS compared with group 2 (adj. Pâ€‰<â€‰0.01), but not with group 3. Additionally, group 4 showed a significantly lower risk of LRR than group 3. In the CRT cohort, group 4 was associated with improved OS compared with group 1 (adj. Pâ€‰=â€‰0.005); however, this association was not retained in surgical patients. No significant differences in DFS, DM, or LRR were observed across groups in the CRT cohort.<br><br>In TNT cohort, minimum 18 weeks of chemotherapy was associated with improved OS and DFS compared to 3 to 12 weeks. The observed OS benefit of minimum 18 weeks versus no chemotherapy in the CRT cohort was not retained among surgical patients. These findings suggest caution in shortening chemotherapy duration, particularly in high-risk patients treated with TNT, and warrant confirmation in prospective TNT-specific trials.<br><br>The STELLAR trial was registered at ClinicalTrials.gov (identifier: NCT02533271); however, this post hoc analysis was retrospectively conducted.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742206/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742206')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742206" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.\nğŸ¥ BMC medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742206/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Diseases (Basel, Switzerland)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ Anti-TNF ìœ ì§€/TDM ê³ ë ¤</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ Dose escalation ê³ ë ¤</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Upadacitinib demonstrates significant clinical and endoscopic efficacy in biologic-experienced, anti-TNF-pretreated patients with CD, achieving remission rates comparable to or exceeding those of the pivotal trials despite a highly refractory population (75% with â‰¥3 prior biologic failures). The favorable safety profile supports upadacitinib as an important therapeutic option in sequential treatment of refractory CD.</div>
            <div class="abs">The efficacy of upadacitinib in patients with Crohn's disease (CD) has been shown in pivotal randomized controlled trials. However, real-world data is needed to assess its effectiveness and safety in routine clinical care with biologic-experienced patients. This study aimed to evaluate the clinical and endoscopic efficacy, patient-reported outcomes (PROs), and safety of upadacitinib in biologic-experienced patients with CD in a real-world setting.<br><br>This prospective bi-centric real-world study enrolled 28 anti-TNF-experienced patients with CD receiving upadacitinib 45 mg daily for 12 weeks (induction), followed by 30 mg daily maintenance through week 52. Primary endpoints included endoscopic response (â‰¥50% SES-CD reduction or â‰¥2-point decrease from baseline for baseline SES-CD â‰¤ 4) and clinical remission (Harvey-Bradshaw Index [HBI] â‰¤ 4). Secondary endpoints included endoscopic remission, clinical response (HBI decrease â‰¥ 3 points), and quality of life (IBD-Disk). Statistical analysis used the Wilcoxon signed-rank test with 95% confidence intervals (CIs).<br><br>Median patient age was 37 years; 75% had â‰¥3 prior biologic failures. Clinical remission rates (HBI) were 59% (95% CI: 41-75%) at week 12, 44% (95% CI: 27-63%) at week 26, and 53% (95% CI: 29-76%) at week 52. Endoscopic response rates were 48% (95% CI: 44-52%) at week 26 and 46% (95% CI: 21-72%) at week 52. Endoscopic remission was achieved in 43% (95% CI: 40-48%) at week 26 and 27% (95% CI: 10-57%) at week 52. Clinical response (HBI) improved progressively from 65% at week 2 to 71% at week 52. Quality of life, as assessed by the IBD-Disk, showed significant improvement: Reduced Disease Burden (defined as a decrease of 70% or a CED-Disk Score of â‰¤15) was observed in 33% of patients at week 12 and 35% at week 52. Median SES-CD decreased from 9 points (IQR: 6-17) at baseline to 5 points (IQR: 1-12, <br><br>Upadacitinib demonstrates significant clinical and endoscopic efficacy in biologic-experienced, anti-TNF-pretreated patients with CD, achieving remission rates comparable to or exceeding those of the pivotal trials despite a highly refractory population (75% with â‰¥3 prior biologic failures). The favorable safety profile supports upadacitinib as an important therapeutic option in sequential treatment of refractory CD.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745092/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745092')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745092" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.\nğŸ¥ Diseases (Basel, Switzerland)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745092/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 9.3</span> <b>Gastrointestinal endoscopy</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>American Society for Gastrointestinal Endoscopy standards for fellowship training in peroral endoscopic myotomy.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This consensus effort provides evidence-based minimum standards for POEM training, applicable to both GI and surgical trainees. These recommendations are intended to guide the structure of training programs, ensure safe dissemination of POEM, and support the evolution of competency-based education in third-space endoscopy.</div>
            <div class="abs">Peroral endoscopic myotomy (POEM) is a complex, technically demanding endoscopic procedure that requires focused, structured training. While increasingly adopted in both gastroenterology and surgical practice, there has been no consensus-based guidance to establish adequate training standards in POEM. Using a validated consensus methodology, we aimed to define minimum standards for POEM training programs to ensure competence in technical, cognitive, and integrative skills necessary for safe and effective practice.<br><br>A multidisciplinary expert panel was convened by the American Society for Gastrointestinal Endoscopy. The Research and Development (RAND)/University of California, Los Angeles appropriateness method (RAM) was used to evaluate candidate statements across 5 domains: pretraining activities, structure of training programs, POEM-specific cognitive training, POEM-specific technical training, and assessment of competence. Experts participated in 2 rounds of voting, rating each statement on a 9-point scale from highly inappropriate (1) to highly appropriate (9). For each statement, the median score and mean absolute deviation from the median were calculated. A statement was considered appropriate if it received a median score â‰¥7 and met the criteria for appropriateness based on the BIOMED, Interpercentile Range Adjusted for Symmetry, and P value methods.<br><br>Of the 40 proposed statements, 34 met the criteria as appropriate. Key recommendations included that trainees should undergo POEM training within programs performing at least 40 procedures annually, be mentored by at least 1 trainer with â‰¥100 prior POEMs, and complete a minimum of 15 POEMs before undergoing milestone assessments with a validated assessment tool. Cognitive requirements included mastery of mediastinal anatomy, GERD management, electrosurgical tools, and interpretation of motility and imaging studies. Simulation model training and exposure to esophageal POEM, gastric POEM, and Zenker POEM were also recommended.<br><br>This consensus effort provides evidence-based minimum standards for POEM training, applicable to both GI and surgical trainees. These recommendations are intended to guide the structure of training programs, ensure safe dissemination of POEM, and support the evolution of competency-based education in third-space endoscopy.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41739032/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41739032')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41739032" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ American Society for Gastrointestinal Endoscopy standards for fellowship training in peroral endoscopic myotomy.\nğŸ¥ Gastrointestinal endoscopy\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739032/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Blood</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by age-related somatic mutations in hematopoietic stem and progenitor cells (HSC/Ps) and is correlated with an increased risk of myeloid malignancies, elevated inflammatory pathways in circulating myeloid cells, higher all-cause mortality, chronic kidney disease, and cardiovascular disease. The pathophysiology of inflammatory bowel disease (IBD) is intrinsically linked to heightened inflammation. Nevertheless, the presence of CHIP in IBD and its role in the pathophysiology of IBD remains poorly elucidated. In the UK Biobank, CHIP was associated with an increased incidence of IBD. Females with CHIP had a 1.33-fold higher risk, which was further validated in All of Us data base (ÃŸOR = 1.29). For Crohn's disease, DNMT3A mutations conferred a 1.81-fold increased incidence in females compared to non-DNMT3A-carriers, which rose to 2.09 for large clones (variant allele fraction â‰¥10%). In contrast, for ulcerative colitis, TET2 large clones were significantly associated, and only among individuals under 45. These associations were further identified using two-sample Mendelian randomization. In a mouse model of CHIP-IBD, HSC/Ps with Dnmt3a mutation demonstrated significantly worse pathophysiology compared to controls, due in part to heightened expression of Apurinic/apyrimidinic endonuclease 1 (APE1) in the bone marrow and colon. Treatment with the APE1/Ref-1 inhibitor APX3330 ameliorated CHIP-IBD driven by the Dnmt3a mutation.</div>
            <div class="abs">Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by age-related somatic mutations in hematopoietic stem and progenitor cells (HSC/Ps) and is correlated with an increased risk of myeloid malignancies, elevated inflammatory pathways in circulating myeloid cells, higher all-cause mortality, chronic kidney disease, and cardiovascular disease. The pathophysiology of inflammatory bowel disease (IBD) is intrinsically linked to heightened inflammation. Nevertheless, the presence of CHIP in IBD and its role in the pathophysiology of IBD remains poorly elucidated. In the UK Biobank, CHIP was associated with an increased incidence of IBD. Females with CHIP had a 1.33-fold higher risk, which was further validated in All of Us data base (ÃŸOR = 1.29). For Crohn's disease, DNMT3A mutations conferred a 1.81-fold increased incidence in females compared to non-DNMT3A-carriers, which rose to 2.09 for large clones (variant allele fraction â‰¥10%). In contrast, for ulcerative colitis, TET2 large clones were significantly associated, and only among individuals under 45. These associations were further identified using two-sample Mendelian randomization. In a mouse model of CHIP-IBD, HSC/Ps with Dnmt3a mutation demonstrated significantly worse pathophysiology compared to controls, due in part to heightened expression of Apurinic/apyrimidinic endonuclease 1 (APE1) in the bone marrow and colon. Treatment with the APE1/Ref-1 inhibitor APX3330 ameliorated CHIP-IBD driven by the Dnmt3a mutation.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41746260/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41746260')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41746260" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.\nğŸ¥ Blood\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41746260/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Toxins</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Indoxyl Sulfate in the Gut-Kidney Axis: Pathophysiology and Clinical Significance in CKD-Associated Colorectal Cancer.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Chronic Kidney Disease (CKD) and Colorectal Cancer (CRC) share a profound epidemiological link, supported by Mendelian randomization studies suggesting causality. This review articulates a refined Gut-Kidney Axis, focusing on the pathophysiology of indole-derived uremic toxins. CKD-induced dysbiosis drives hepatic synthesis and systemic accumulation of indoxyl sulfate, which is proposed to promote carcinogenesis via Aryl Hydrocarbon Receptor (AhR) and Akt signaling, ultimately upregulating </div>
            <div class="abs">Chronic Kidney Disease (CKD) and Colorectal Cancer (CRC) share a profound epidemiological link, supported by Mendelian randomization studies suggesting causality. This review articulates a refined Gut-Kidney Axis, focusing on the pathophysiology of indole-derived uremic toxins. CKD-induced dysbiosis drives hepatic synthesis and systemic accumulation of indoxyl sulfate, which is proposed to promote carcinogenesis via Aryl Hydrocarbon Receptor (AhR) and Akt signaling, ultimately upregulating </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745738/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745738')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745738" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Indoxyl Sulfate in the Gut-Kidney Axis: Pathophysiology and Clinical Significance in CKD-Associated Colorectal Cancer.\nğŸ¥ Toxins\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745738/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of personalized medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ IL-12/23 ë°˜ì‘ í‰ê°€</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="abs">Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745409/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745409')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745409" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.\nğŸ¥ Journal of personalized medicine\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745409/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸº Liver Track</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of liver cancer</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> âœ… ìš°ì„  ì ìš© ê³ ë ¤</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial, particularly regarding liver resection (LR), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This meta-analysis aims to evaluate the overall survival (OS) and disease-free survival (DFS) in patients with multinodular BCLC-A HCC treated with LR compared to RFA and TACE. A systematic literature review and meta-analysis were performed by searching PubMed, Embase, and the Cochrane Library for studies comparing LR with RFA and TACE. Pooled analyses of overall survival (OS) and disease-free survival (DFS) were performed using Hazard Ratios (HR) with 95% confidence intervals (CI). Fifteen studies, including two randomized controlled trials and 13 cohort studies, with a total of 2,869 patients, were included. LR was significantly associated with improved OS (HR 1.38; 95% CI 1.03-1.84; p = 0.01) and DFS (HR 2.16; 95% CI 1.26-3.70; p = 0.001) compared with RFA. Similarly, LR demonstrated superior OS (HR 2.11; 95% CI 1.37-3.25; p < 0.0001) and DFS (HR 2.77; 95% CI 1.04-7.36; p = 0.04) when compared with TACE. The more pronounced benefit observed for DFS likely reflects improved local tumor control achieved with surgical resection. In selected patients with multinodular BCLC-A HCC and preserved liver function (predominantly Child-Pugh A or B), LR is associated with significant improvements in OS and DFS compared with RFA and TACE when liver transplantation is not feasible. These findings support reconsideration of current treatment algorithms to prioritize LR in appropriately selected candidates.</div>
            <div class="abs">Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial, particularly regarding liver resection (LR), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This meta-analysis aims to evaluate the overall survival (OS) and disease-free survival (DFS) in patients with multinodular BCLC-A HCC treated with LR compared to RFA and TACE. A systematic literature review and meta-analysis were performed by searching PubMed, Embase, and the Cochrane Library for studies comparing LR with RFA and TACE. Pooled analyses of overall survival (OS) and disease-free survival (DFS) were performed using Hazard Ratios (HR) with 95% confidence intervals (CI). Fifteen studies, including two randomized controlled trials and 13 cohort studies, with a total of 2,869 patients, were included. LR was significantly associated with improved OS (HR 1.38; 95% CI 1.03-1.84; p = 0.01) and DFS (HR 2.16; 95% CI 1.26-3.70; p = 0.001) compared with RFA. Similarly, LR demonstrated superior OS (HR 2.11; 95% CI 1.37-3.25; p < 0.0001) and DFS (HR 2.77; 95% CI 1.04-7.36; p = 0.04) when compared with TACE. The more pronounced benefit observed for DFS likely reflects improved local tumor control achieved with surgical resection. In selected patients with multinodular BCLC-A HCC and preserved liver function (predominantly Child-Pugh A or B), LR is associated with significant improvements in OS and DFS compared with RFA and TACE when liver transplantation is not feasible. These findings support reconsideration of current treatment algorithms to prioritize LR in appropriately selected candidates.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742714/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742714')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742714" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis.\nğŸ¥ Journal of liver cancer\nâš¡ âœ… ìš°ì„  ì ìš© ê³ ë ¤\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742714/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Giornale italiano di cardiologia (2006)</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>[Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="abs">The introduction of non-dilated left ventricular cardiomyopathy (NDLVC) represents one of the key highlights of the 2023 European Society of Cardiology guidelines on cardiomyopathies. NDLVC is defined by the presence of left ventricular systolic dysfunction in the absence of ventricular dilation and/or non-ischemic myocardial fibrosis detectable by cardiac magnetic resonance. The clinical manifestation may be arrhythmogenic, with a risk of life-threatening ventricular arrhythmias even in patients with preserved ejection fraction. The phenotypic heterogeneity and variability in clinical expression reflect the complex interplay between genetic predisposition (involving variants in genes such as FLNC, DSP, and LMNA) and environmental, epigenetic, or inflammatory factors. A synergistic approach combining comprehensive clinical and family assessment, electrocardiographic and echocardiographic findings, advanced imaging, and genetic testing enables more accurate phenotypic characterization, definitive diagnosis, and consequently, tailored therapeutic strategies.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738421/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738421')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738421" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ [Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].\nğŸ¥ Giornale italiano di cardiologia (2006)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738421/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>American journal of respiratory and critical care medicine</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Identification of a conserved sequence of disease progression in Idiopathic Pulmonary Fibrosis.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ Dose escalation ê³ ë ¤</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>We identified a conserved sequential decline in lung function in IPF, which has important implications for the design of clinical trials. The DPM provides a powerful framework to investigate the clinical and/or biological processes that initiate and propagate IPF.</div>
            <div class="abs">Idiopathic pulmonary fibrosis (IPF) begins years before symptoms appear, but the natural history is incompletely understood.<br><br>To describe and quantify IPF disease progression using four pulmonary function test (PFT) parameters.<br><br>Two cohorts included 245 adults with subclinical through advanced familial pulmonary fibrosis (FPF) or 347 placebo-treated IPF patients enrolled in two randomized controlled trials (RCTs). A Bayesian joint repeated measures model was fit to describe the observed PFT values as a function of the estimated years since onset (EYO). A latent variable estimated the subject-level chronological age at onset. Onset was assumed to occur when the diffusion capacity for carbon monoxide (DLCO) was 70%-predicted. The relationships between EYO and clinical outcomes not included in the model (e.g., transplant-free survival) were evaluated, adjusting for age and sex.<br><br>In FPF, the DLCO declined steadily starting around EYO -10, reaching 86.8%-predicted by EYO -5 and 45.3%-predicted byâ€‰+â€‰5. The forced vital capacity (FVC) declined later, reaching 98.6%-predicted by EYO -5 and 76.2%-predicted byâ€‰+â€‰5. The annualized decline in FVC was 12-fold greater in the year after EYO + 5 (6.14%-predicted) than -5 (0.49%-predicted). There was a 31% higher risk of death or transplant (HR 1.31, 95% CI 1.25-1.37) per 1-year increase in EYO. Similar findings were observed in the RCTs.<br><br>We identified a conserved sequential decline in lung function in IPF, which has important implications for the design of clinical trials. The DPM provides a powerful framework to investigate the clinical and/or biological processes that initiate and propagate IPF.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738263/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738263')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738263" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Identification of a conserved sequence of disease progression in Idiopathic Pulmonary Fibrosis.\nğŸ¥ American journal of respiratory and critical care medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738263/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>American journal of respiratory and critical care medicine</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>In the FIBRONEER-IPF trial, nerandomilast had no effect on the composite endpoint of time to first acute exacerbation, hospitalization for respiratory cause, or death, but nerandomilast 18â€‰mg bid was associated with a numerically lower risk of death. Nerandomilast had a favorable safety profile, with a low rate of discontinuation due to adverse events.</div>
            <div class="abs">In the randomized placebo-controlled FIBRONEER-IPF trial in patients with idiopathic pulmonary fibrosis, both nerandomilast 9â€‰mg bid and 18â€‰mg bid met the primary endpoint of reducing decline in forced vital capacity at week 52. Patients continued to receive randomized treatment after week 52, until the last patient had completed an end-of-treatment visit.<br><br>To assess the effects of nerandomilast over the full duration of follow-up in the FIBRONEER-IPF trial.<br><br>Time to first acute exacerbation, hospitalization for respiratory cause, or death (key secondary endpoint) and other time-to-event endpoints were assessed at final database lock.<br><br>1177 patients were treated. Mean (SD) exposure to trial medication was 14.8 (5.0), 14.9 (5.0) and 14.7 (5.3) months in the placebo, nerandomilast 9â€‰mg bid and nerandomilast 18â€‰mg bid groups, respectively. Compared with placebo, the hazard ratio (95% CI) for the key secondary endpoint was 0.92 (0.69, 1.22) for nerandomilast 9â€‰mg bid and 0.99 (0.75, 1.31) for nerandomilast 18â€‰mg bid and the hazard ratio (95% CI) for death was 0.95 (0.61, 1.49) for nerandomilast 9â€‰mg bid and 0.66 (0.41, 1.08) for nerandomilast 18â€‰mg bid. Adverse events led to treatment discontinuation in 13.0%, 13.5% and 16.1% of the placebo, nerandomilast 9â€‰mg bid and nerandomilast 18â€‰mg bid groups, respectively.<br><br>In the FIBRONEER-IPF trial, nerandomilast had no effect on the composite endpoint of time to first acute exacerbation, hospitalization for respiratory cause, or death, but nerandomilast 18â€‰mg bid was associated with a numerically lower risk of death. Nerandomilast had a favorable safety profile, with a low rate of discontinuation due to adverse events.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738262/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738262')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738262" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.\nğŸ¥ American journal of respiratory and critical care medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738262/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 13.5</span> <b>Hepatology (Baltimore, Md.)</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.</div>
            <div class="abs">Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This study developed and validated a model integrating clinicopathological and radiomic features of tumor to predict pCR.<br><br>In this multi-center retrospective study, temporal radiomics features were extracted from baseline, post-treatment, and delta (change) MRIs. Serum AFP response was calculated as logâ‚â‚€(preoperative AFP)/logâ‚â‚€(baseline AFP). Univariate analysis, collinearity assessment, LASSO, and random forest were employed to perform feature selection. Fourteen machine learning models were benchmarked, with performance evaluated by using comprehensive metrics AUC, NPV, PPV, sensitivity, specificity, calibration, and decision curve analysis.<br><br>The model was developed and validated in a training (n=78), an internal test (n=32), and an independent validation cohort (n=44). The delta radiomic model significantly outperformed both baseline (test AUC: 0.835 vs. 0.483, p<0.05; validation AUC: 0.783 vs. 0.434, p<0.05) and preoperative models (test AUC: 0.685, p<0.05; validation AUC: 0.506, p<0.05), demonstrating superior predictive performance and generalization capability in predicting lesion-level pCR. Notably, when predicting patient-level pCR, the radiomic model also showed robust discrimination, with AUCs of 0.819 in the test set and 0.781 in the validation set.The combined radiomics-AFP model achieved even higher AUCs of 0.920 (test) and 0.857 (validation) in predicting lesion-level pCR.<br><br>Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41746634/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41746634')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41746634" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.\nğŸ¥ Hepatology (Baltimore, Md.)\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41746634/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Toxins</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Aflatoxin and Liver Cancer in China: The Evolving Research Landscape.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Aflatoxins, particularly aflatoxin B</div>
            <div class="abs">Aflatoxins, particularly aflatoxin B</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41745727/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41745727')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41745727" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Aflatoxin and Liver Cancer in China: The Evolving Research Landscape.\nğŸ¥ Toxins\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41745727/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Journal of proteome research</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Enrichment and Preservation of Urine Metabolites Using Styrene Divinylbenzene Reversed Phase Sulfonate (SDB-RPS) Disks for Enhanced Biomarker Discovery and Disease Monitoring.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Urine metabolomics plays a crucial role in biomarker discovery and disease monitoring, but challenges in metabolite preservation remain. This study evaluates the use of styrene divinylbenzene reversed phase sulfonate (SDB-RPS) disks for enriching and preserving urine metabolites utilizing ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) for analysis. We compared SDB-RPS-enriched urine samples with untreated urine across three experimental parts: (1) metabolic profiling using C18 and HILIC chromatography under both positive and negative ion modes; (2) degradation kinetics, where SDB-RPS and untreated urine samples were incubated at 55, 65, and 75 Â°C with constant humidity (75%); and (3) disease classification using hepatitis (</div>
            <div class="abs">Urine metabolomics plays a crucial role in biomarker discovery and disease monitoring, but challenges in metabolite preservation remain. This study evaluates the use of styrene divinylbenzene reversed phase sulfonate (SDB-RPS) disks for enriching and preserving urine metabolites utilizing ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) for analysis. We compared SDB-RPS-enriched urine samples with untreated urine across three experimental parts: (1) metabolic profiling using C18 and HILIC chromatography under both positive and negative ion modes; (2) degradation kinetics, where SDB-RPS and untreated urine samples were incubated at 55, 65, and 75 Â°C with constant humidity (75%); and (3) disease classification using hepatitis (</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41744491/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41744491')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41744491" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Enrichment and Preservation of Urine Metabolites Using Styrene Divinylbenzene Reversed Phase Sulfonate (SDB-RPS) Disks for Enhanced Biomarker Discovery and Disease Monitoring.\nğŸ¥ Journal of proteome research\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41744491/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Liver international : official journal of the International Association for the Study of the Liver</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Saroglitazar 4â€‰Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Saroglitazar 4â€‰mg for 24â€‰weeks was associated with improvements in surrogate markers of liver injury, steatosis, glycaemic control and lipid metabolism, with good tolerability. These interim real-world findings support further evaluation in the planned 52-week analysis.</div>
            <div class="abs">Saroglitazar magnesium, a dual PPAR Î±/Î³ agonist, is approved in India for the treatment of non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD). While controlled trials with saroglitazar have demonstrated improvements in hepatic and metabolic parameters in patients with MASLD, real-world data in populations with diverse metabolic comorbidities remain limited.<br><br>This is an ongoing, prospective, single-arm, multicenter, real-world, phase 4 study evaluating the effectiveness and safety of saroglitazar 4â€‰mg once daily in patients with MASLD. The current interim analysis includes 500 patients who completed 24â€‰weeks of treatment. Changes in liver stiffness measurement (LSM), hepatic steatosis (CAP and UAP), glycemic control, lipid profile, liver enzymes and non-invasive fibrosis scores were assessed. Safety was evaluated based on treatment-emergent adverse events (TEAEs). This was a non-protocol-defined, exploratory interim analysis; all statistical inferences are descriptive and p-values are nominal.<br><br>At baseline, the mean age was 45.7â€‰Â±â€‰11.6â€‰years, weight 81.0â€‰Â±â€‰13.6â€‰kg, body mass index (BMI) 29.9â€‰Â±â€‰4.7â€‰kg/m<br><br>In this interim real-world analysis, saroglitazar 4â€‰mg was associated with improvements in liver stiffness, hepatic steatosis, metabolic parameters and non-invasive fibrosis markers in patients with MASLD. The treatment was generally well tolerated. These findings warrant further confirmation upon completion of the 52-week analysis.<br><br>Saroglitazar 4â€‰mg for 24â€‰weeks was associated with improvements in surrogate markers of liver injury, steatosis, glycaemic control and lipid metabolism, with good tolerability. These interim real-world findings support further evaluation in the planned 52-week analysis.<br><br>CTRI/2023/05/053326 [Registered on: 31/05/2023].</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41742827/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41742827')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41742827" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Saroglitazar 4â€‰Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.\nğŸ¥ Liver international : official journal of the International Association for the Study of the Liver\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41742827/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>The Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Reducing Pathologic Scar Formation After Median Sternotomy.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This study aimed to investigate the effects of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on pathological scar formation, following median sternotomy, focusing on the role of the renin-angiotensin system (RAS) in tissue remodelling and wound healing. Designed as a cross-sectional observational study, it included 100 patients who had undergone median sternotomy at least 6â€‰months prior and were receiving continuous antihypertensive treatment. Patients were categorised into three groups based on their medications: ACEIs (nâ€‰=â€‰33), ARBs (nâ€‰=â€‰35), and other antihypertensives (nâ€‰=â€‰32). Scar formation was evaluated using the Patient and Observer Scar Assessment Scale (POSAS v2.0), which assesses both subjective and objective parameters. The study showed that keloid formation was significantly less common in the ACEI (24.2%) and ARB (25.7%) groups compared to the group using other antihypertensives (53.1%, pâ€‰=â€‰0.021). Both OSAS and PSAS total scores were significantly lower in the ACEI and ARB groups (pâ€‰=â€‰0.036 and pâ€‰=â€‰0.042, respectively). Among OSAS subparameters, vascularization (pâ€‰=â€‰0.005), pigmentation (pâ€‰=â€‰0.012), thickness (pâ€‰=â€‰0.010), and surface appearance (pâ€‰=â€‰0.007) were significantly improved in the ACEI and ARB groups. Among PSAS subparameters, pain (pâ€‰=â€‰0.003), stiffness (pâ€‰=â€‰0.021), thickness (pâ€‰=â€‰0.013), and irregularity (pâ€‰=â€‰0.025) were significantly lower in these groups compared to the other antihypertensives group. Our findings suggest that ACEIs and ARBs, commonly used for hypertension, may be associated with improved scar quality and a reduced tendency for keloid formation. These medications could represent a promising and cost-effective alternative to traditional scar treatments, particularly in hypertensive patients. However, given the cross-sectional design of our study and the variability in postoperative durations among patients, these findings should be interpreted as exploratory. While associations were observed, causality remains uncertain. Further larger, prospective, randomised controlled studies with standardised evaluation times and detailed information on medications and dosages are needed to better clarify the potential role of ACEIs and ARBs in scar management.</div>
            <div class="abs">This study aimed to investigate the effects of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on pathological scar formation, following median sternotomy, focusing on the role of the renin-angiotensin system (RAS) in tissue remodelling and wound healing. Designed as a cross-sectional observational study, it included 100 patients who had undergone median sternotomy at least 6â€‰months prior and were receiving continuous antihypertensive treatment. Patients were categorised into three groups based on their medications: ACEIs (nâ€‰=â€‰33), ARBs (nâ€‰=â€‰35), and other antihypertensives (nâ€‰=â€‰32). Scar formation was evaluated using the Patient and Observer Scar Assessment Scale (POSAS v2.0), which assesses both subjective and objective parameters. The study showed that keloid formation was significantly less common in the ACEI (24.2%) and ARB (25.7%) groups compared to the group using other antihypertensives (53.1%, pâ€‰=â€‰0.021). Both OSAS and PSAS total scores were significantly lower in the ACEI and ARB groups (pâ€‰=â€‰0.036 and pâ€‰=â€‰0.042, respectively). Among OSAS subparameters, vascularization (pâ€‰=â€‰0.005), pigmentation (pâ€‰=â€‰0.012), thickness (pâ€‰=â€‰0.010), and surface appearance (pâ€‰=â€‰0.007) were significantly improved in the ACEI and ARB groups. Among PSAS subparameters, pain (pâ€‰=â€‰0.003), stiffness (pâ€‰=â€‰0.021), thickness (pâ€‰=â€‰0.013), and irregularity (pâ€‰=â€‰0.025) were significantly lower in these groups compared to the other antihypertensives group. Our findings suggest that ACEIs and ARBs, commonly used for hypertension, may be associated with improved scar quality and a reduced tendency for keloid formation. These medications could represent a promising and cost-effective alternative to traditional scar treatments, particularly in hypertensive patients. However, given the cross-sectional design of our study and the variability in postoperative durations among patients, these findings should be interpreted as exploratory. While associations were observed, causality remains uncertain. Further larger, prospective, randomised controlled studies with standardised evaluation times and detailed information on medications and dosages are needed to better clarify the potential role of ACEIs and ARBs in scar management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41738300/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41738300')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41738300" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ The Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Reducing Pathologic Scar Formation After Median Sternotomy.\nğŸ¥ Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738300/</textarea>
        </div>
    </details></div><div class='sec-group'><h3>ğŸ§¬ Biliary/Pancreas</h3>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"><span class='badge if'>IF 13.5</span> <b>JHEP reports : innovation in hepatology</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ HCC surveillance ì¬ì„¤ì •</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>HCC recurrence was rare after transplantation of livers treated with HOPE. Long-term survival in HOPE-treated HCC recipients was significantly better than in those receiving non-perfused livers, and comparable to outcomes in non-HCC recipients. These findings warrant validation in a randomized clinical trial.</div>
            <div class="abs">Liver transplantation (LT) for hepatocellular carcinoma (HCC) is performed worldwide, with 5-year survival rates of approximately 70%. However, post-transplant HCC recurrence occurs in 15-20% of recipients. We aimed to evaluate, for the first time, long-term recurrence-free survival in a large international cohort of patients undergoing LT for HCC using grafts treated with hypothermic oxygenated machine perfusion (HOPE).<br><br>This observational <br><br>The overall HCC recurrence rate in the HOPE-REAL cohort was 6.9% (41/599), with no significant difference between DBD and DCD liver transplants (7.1% [25/350] <br><br>HCC recurrence was rare after transplantation of livers treated with HOPE. Long-term survival in HOPE-treated HCC recipients was significantly better than in those receiving non-perfused livers, and comparable to outcomes in non-HCC recipients. These findings warrant validation in a randomized clinical trial.<br><br>This <br><br>NCT05520320.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41737541/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41737541')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41737541" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.\nğŸ¥ JHEP reports : innovation in hepatology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41737541/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Frontiers in pharmacology</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.</div>
            <div class="abs">Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.<br><br>A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.<br><br>GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68-0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68-0.96) and liver cancer (HR: 0.74; 95% CI: 0.62-0.88). Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61-0.95). Findings were consistent across sensitivity analyses.<br><br>This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered in Open Science Framework https://osf.io/3rv6d/overview.<br><br>https://osf.io/3rv6d/overview.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41743116/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41743116')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41743116" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.\nğŸ¥ Frontiers in pharmacology\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41743116/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Annals of surgery</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis.</div>
            <div class="abs">To examine long-term and oncologic outcomes of broad-spectrum perioperative antimicrobial prophylaxis, compared with standard care antibiotics, in patients undergoing pancreatoduodenectomy.<br><br>A registry-linked randomized clinical trial demonstrated a reduction in surgical site infection (SSI) in patients undergoing pancreatoduodenectomy who received piperacillin-tazobactam as perioperative prophylaxis compared to cefoxitin. However, long-term outcomes remain undefined.<br><br>Participant records from the American College of Surgeons National Surgical Quality Improvement Program database were matched to the National Cancer Database. Associations between treatment arm, perioperative complications, and oncologic outcomes were assessed. Logistic regression models investigated associations with oncologic outcomes. Survival analyses used Kaplan Meier and Cox proportional hazard modeling.<br><br>Of 778 patients, 471 (60.5%) were treated at Commission on Cancer accredited hospitals and eligible for linkage. Of those, 426 (90.4%) were matched in the NCDB including 203 (47.7%) treated with piperacillin-tazobactam and 223 (52.3%) with cefoxitin. Among patients with indications for chemotherapy, chemotherapy omission rates were similar between the treatment arms (9.4% in piperacillin-tazobactam vs 15.4% in cefoxitin; P=0.097). There was no association between the receipt of indicated adjuvant chemotherapy and receipt of piperacillin-tazobactam (OR 1.49; 95% CI 0.56-3.95) or presence of SSI (OR 0.58; 95% CI 0.21-1.65). Postoperative SSI was associated with poorer 3-year overall survival (HR 1.69, 95% CI 1.20-2.38).<br><br>While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41731645/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41731645')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41731645" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy.\nğŸ¥ Annals of surgery\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41731645/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>The oncologist</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>The overall safety of atezolizumab combinations was manageable and consistent with each agent's known safety profile. This novel trial design enabled rapid evaluations of three atezolizumab combinations; all had limited efficacy as 2â€‰L or 3â€‰L treatment for metastatic PDAC. New treatments are needed to improve outcomes in previously treated PDAC.</div>
            <div class="abs">The MORPHEUS platform comprised multiple open-label, randomized, phase Ib/II trials to identify early signals with different treatment combinations across multiple cancers. MORPHEUS-PDAC (NCT03193190) evaluated atezolizumab combinations in pancreatic ductal adenocarcinoma (PDAC). We describe outcomes with atezolizumab plus either motixafortide, cobimetinib, or two simlukafusp alfa regimens.<br><br>Eligible patients with advanced, pretreated PDAC were randomized to receive second-line (2â€‰L) atezolizumab plus either motixafortide (BL8040; nâ€‰=â€‰15), cobimetinib (nâ€‰=â€‰14), simlukafusp alfa every 2â€‰weeks (q2w; nâ€‰=â€‰15), or simlukafusp alfa every 3â€‰weeks (q3w; nâ€‰=â€‰16); or control (mFOLFOX6 [nâ€‰=â€‰25] or gemcitabine plus nab-paclitaxel [nâ€‰=â€‰25]). Patients experiencing disease progression or toxicity who met eligibility criteria were enrolled to receive third-line (3â€‰L) atezolizumab plus cobimetinib (nâ€‰=â€‰14), or atezolizumab plus simlukafusp alfa q2w (nâ€‰=â€‰1) or q3w (nâ€‰=â€‰6). Primary endpoints were objective response rates (ORRs) per RECIST 1.1 and safety.<br><br>ORRs were 7.1% with atezolizumab-simlukafusp alfa q2w, 8.7% with mFOLFOX6 (both 2â€‰L; 0% in other arms), 14.3% with atezolizumab-cobimetinib, and 16.7% with atezolizumab-simlukafusp alfa q3w (both 3â€‰L). Grade 3-5 adverse event rates were 53.3% (2â€‰L atezolizumab-motixafortide), 64.3% (2â€‰L atezolizumab-cobimetinib), 57.1% (2â€‰L atezolizumab-simlukafusp alfa q2w), 53.3% (2â€‰L atezolizumab-simlukafusp alfa q3w), 63.0% (2â€‰L mFOLFOX6 or gemcitabine-nab-paclitaxel), 50.0% (3â€‰L atezolizumab-cobimetinib), and 100% (3â€‰L atezolizumab-simlukafusp alfa q3w).<br><br>The overall safety of atezolizumab combinations was manageable and consistent with each agent's known safety profile. This novel trial design enabled rapid evaluations of three atezolizumab combinations; all had limited efficacy as 2â€‰L or 3â€‰L treatment for metastatic PDAC. New treatments are needed to improve outcomes in previously treated PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41741368/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41741368')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41741368" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.\nğŸ¥ The oncologist\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41741368/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Dual calcium-ACE inhibition reverses non alcoholic fatty pancreas progression: Mechanistic convergence on miR-762/GPX4 driven NLRP3 inflammasome activation.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>These findings position miR-762 as a linchpin biomarker connecting metabolic stress to ferroptotic pancreatitis, with clinical translation challenges. This work provides the first evidence that sub-therapeutic calcium-RAS crosstalk modulation can reverse established pancreatic steatosis while outlining a precision medicine framework for NAFP prevention.</div>
            <div class="abs">Non-alcoholic fatty pancreas (NAFP) is characterized by abnormal pancreatic fat accumulation and remains poorly understood.<br><br>This study investigates the therapeutic potential and mechanistic basis of low-dose amlodipine-perindopril combination therapy, hypothesizing dual calcium channel blockade and RAS inhibition synergistically disrupt ferroptotic-inflammatory cascades driving pancreatic lipotoxicity.<br><br>The bioinformatics analysis of GEO datasets (GSE40901, GSE101462, and GSE194331) identified differentially expressed genes, which were further validated through molecular docking studies with amlodipine and perindoprilat. Male Wistar rats (nâ€¯=â€¯30) were randomized into five groups: healthy control, NAFP (high-sugar/high-fat diet), amlodipine-treated, perindopril-treated, and combination therapy. Gene expression of GPX4, ACSL4, NLRP3, and rno-miR-762 was quantified by Real-Time PCR. Metabolic parameters, pancreatic histopathology, and immunohistochemical markers (caspase-1, nuclear factor kappa B (NF-ÎºB)) were assessed.<br><br>Bioinformatics analysis revealed significant alterations in ferroptosis and inflammatory pathways. Molecular docking demonstrated favorable binding affinities between therapeutic compounds and target proteins. NAFP induction resulted in GPX4 downregulation (0.471â€¯Â±â€¯0.357 vs. 1.197â€¯Â±â€¯0.449, Pâ€¯<â€¯0.05), ACSL4 upregulation (48.633â€¯Â±â€¯40.998 vs. 1.197â€¯Â±â€¯0.445, pâ€¯<â€¯0.001), elevated NLRP3 (12.717â€¯Â±â€¯7.904 vs. 1.115â€¯Â±â€¯0.186, pâ€¯<â€¯0.001), and increased rno-miR-762 expression. The combination therapy achieved 73â€¯% reduction in pancreatic adipocyte area (vs. 42â€¯% with monotherapies, pâ€¯<â€¯0.001) through coordinated miR-762 suppression (â†“68â€¯%, q=0.003) and GPX4 protein restoration (â†‘2.1-fold, pâ€¯=â€¯0.008). NLRP3 inflammasome activity decreased by 89â€¯% (pâ€¯=â€¯0.004). Crucially, the regimen preserved hemodynamic stability, demonstrating metabolic benefits without cardiovascular compromise.<br><br>These findings position miR-762 as a linchpin biomarker connecting metabolic stress to ferroptotic pancreatitis, with clinical translation challenges. This work provides the first evidence that sub-therapeutic calcium-RAS crosstalk modulation can reverse established pancreatic steatosis while outlining a precision medicine framework for NAFP prevention.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41740369/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41740369')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41740369" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Dual calcium-ACE inhibition reverses non alcoholic fatty pancreas progression: Mechanistic convergence on miR-762/GPX4 driven NLRP3 inflammasome activation.\nğŸ¥ Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740369/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Cancer research communications</b>  ğŸ”¥</div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="abs">Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase 2 study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (antiâ€’PD-1 monoclonal antibody) in select previously treated solid tumors.<br><br>Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg intravenously every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.<br><br>Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% CI) by blinded independent central review were 15.2% (8.7%â€’23.8%) in cohort C, 17.6% (10.8%â€’26.4%) in cohort F, and 7.8% (3.4%â€’14.7%) in cohort G. Grade 3â€’5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3â€’4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.<br><br>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41747221/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41747221')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41747221" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.\nğŸ¥ Cancer research communications\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41747221/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>iScience</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Deficiency of Werner RecQ-type DNA helicase causes premature malnutrition in zebrafish.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>Werner syndrome is a genetic progeria characterized by premature aging symptoms, but its early-onset pathology remains unclear. We generated </div>
            <div class="abs">Werner syndrome is a genetic progeria characterized by premature aging symptoms, but its early-onset pathology remains unclear. We generated </div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41732282/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41732282')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41732282" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Deficiency of Werner RecQ-type DNA helicase causes premature malnutrition in zebrafish.\nğŸ¥ iScience\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41732282/</textarea>
        </div>
    </details>
    <details class="paper-item" style="border-left:4px solid #3498db;background:#fff;">
        <summary>
            <div class="meta"> <b>Medicine</b> </div>
            <div class="title-row"><span class="arrow-icon">â–¶</span>Exploring dietary habits strongly associated with pancreatic cancer from the perspective of Mendelian randomization.</div>
        </summary>
        <div class="content">
            
    <div class='clinical-note'>
        <div><b>ğŸ‘¨â€âš•ï¸ Clinical:</b> ğŸ‘‰ ì„ìƒ íŒë‹¨ í•„ìš”</div>
        <div><b>âš¡ Action:</b> ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”</div>
        <div><b>ğŸ“Œ Order:</b> ğŸ“Œ í™˜ì ë§ì¶¤ íŒë‹¨</div>
    </div>
            <div class='btm-box'><b>ğŸ’¡ Conclusion</b><br>While some retrospective studies have reported that certain dietary habits may affect pancreatic cancer, the variety of dietary habits studied has been limited. A 2-sample Mendelian randomization (MR) analysis was performed using exposure data from the UK Biobank data (nâ€…=â€…10,019,305) and outcome data from the FinnGen database (731 pancreatic cancer cases and 314,193 controls). Instrumental variables were selected based on genome-wide significance, followed by linkage disequilibrium clumping. Sensitivity analyses, including Steiger filtering and MR-PRESSO, were conducted to ensure the robustness of the causal inferences. Following this process, we extracted and filtered the data, ultimately selecting 30 dietary phenotypes from the original 231. Our findings revealed that alcohol intake frequency (raw P-valueâ€…=.002, odds ratio (OR)â€…=â€…1.090, 95% CI: 1.032-1.151) and average weekly spirits intake (raw P-valueâ€…=â€….005, ORâ€…=â€…1.793, 95% CI: 1.196-2.688) were risk factors for pancreatic cancer using data from 706 single nucleotide polymorphisms derived from FinnGen database. Notably, cooked vegetable intake (raw P-valueâ€…=â€….029, ORâ€…=â€…0.704, 95% CI: 0.514-0.965) was found to have a protective effect against pancreatic cancer. Our MR analysis provides evidence that specific dietary habits significantly influence pancreatic cancer risk, highlighting the potential of dietary interventions within public health strategies for pancreatic cancer management.</div>
            <div class="abs">While some retrospective studies have reported that certain dietary habits may affect pancreatic cancer, the variety of dietary habits studied has been limited. A 2-sample Mendelian randomization (MR) analysis was performed using exposure data from the UK Biobank data (nâ€…=â€…10,019,305) and outcome data from the FinnGen database (731 pancreatic cancer cases and 314,193 controls). Instrumental variables were selected based on genome-wide significance, followed by linkage disequilibrium clumping. Sensitivity analyses, including Steiger filtering and MR-PRESSO, were conducted to ensure the robustness of the causal inferences. Following this process, we extracted and filtered the data, ultimately selecting 30 dietary phenotypes from the original 231. Our findings revealed that alcohol intake frequency (raw P-valueâ€…=.002, odds ratio (OR)â€…=â€…1.090, 95% CI: 1.032-1.151) and average weekly spirits intake (raw P-valueâ€…=â€….005, ORâ€…=â€…1.793, 95% CI: 1.196-2.688) were risk factors for pancreatic cancer using data from 706 single nucleotide polymorphisms derived from FinnGen database. Notably, cooked vegetable intake (raw P-valueâ€…=â€….029, ORâ€…=â€…0.704, 95% CI: 0.514-0.965) was found to have a protective effect against pancreatic cancer. Our MR analysis provides evidence that specific dietary habits significantly influence pancreatic cancer risk, highlighting the potential of dietary interventions within public health strategies for pancreatic cancer management.</div>
            <div class="btns">
                <a href="https://pubmed.ncbi.nlm.nih.gov/41731762/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                <button onclick="copyShare('41731762')" class="btn shr">ğŸ“¤ ê³µìœ </button>
            </div>
            <textarea id="s_41731762" style="display:none;">ğŸ“„ GI Intel\nğŸ“Œ Exploring dietary habits strongly associated with pancreatic cancer from the perspective of Mendelian randomization.\nğŸ¥ Medicine\nâš¡ ğŸ§ ì¶”ê°€ íŒë‹¨ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41731762/</textarea>
        </div>
    </details></div>
    </div>

    <footer style="text-align:center; padding:15px; color:#95a5a6; font-size:0.75rem;">ğŸš€ Project: MedProductive Clinical AI</footer>

    <script>
        function toggleF() {
            const btn = document.getElementById('fBtn'); btn.classList.toggle('active');
            const isF = btn.classList.contains('active');
            btn.style.background = isF ? 'var(--success)' : '#fff';
            btn.style.color = isF ? '#fff' : 'var(--success)';
            document.querySelectorAll('.paper-item').forEach(p => {
                p.style.display = isF ? (p.querySelector('.badge-guideline') ? 'block' : 'none') : 'block';
            });
        }
        function copyShare(id) {
            const el = document.getElementById('s_'+id);
            navigator.clipboard.writeText(el.value.replace(/\\n/g, '\n')).then(() => alert("âœ… ë³µì‚¬ ì™„ë£Œ!"));
        }
        
        // ë„ë„› ì°¨íŠ¸ë§Œ ë Œë”ë§
        new Chart(document.getElementById('c2'), { 
            type:'doughnut', 
            data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[8, 9, 8], backgroundColor:['#e74c3c','#f1c40f','#2ecc71']}] }, 
            options: { 
                responsive: true, 
                maintainAspectRatio: false, 
                plugins: { 
                    legend: { position: 'right', labels: { font: { size: 10 } } } 
                } 
            } 
        });
    </script>
</body>
</html>
